A Phase I Open-label Study to Assess the Absolute Bioavailability of Savolitinib and Absorption, Distribution, Metabolism, Excretion of [14C]Savolitinib in Healthy Male Subjects
Latest Information Update: 20 Apr 2023
At a glance
- Drugs Savolitinib (Primary) ; Savolitinib (Primary) ; Savolitinib (Primary)
- Indications CNS cancer; Colorectal cancer; Gastric cancer; Non-small cell lung cancer; Prostate cancer; Renal cell carcinoma
- Focus Pharmacokinetics
- Sponsors AstraZeneca
- 01 Apr 2023 Results published in the Clinical Pharmacology in Drug Development
- 18 Mar 2022 Results presented at the 123rd Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
- 25 Jan 2021 Status changed from active, no longer recruiting to completed.